摘要:2026年上半年医药行业分化态势持续加剧,传统仿制药企业承压前行,不少药企仍在依靠压缩成本维持利润平衡,港股创新药企先声药业却交出一份超预期的业绩预告,打破行业平淡格局。
特别声明:以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布,本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.